{"id":"W2955217622","doi":"10.1016/j.antiviral.2019.104543","title":"Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1","year":2019,"lang":"en","type":"article","venue":"Antiviral Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Health Sciences Centre; Sunnybrook Health Science Centre; University Health Network; University of Toronto; Vancouver Infectious Diseases Centre; Canada Research Chairs; McGill University; Maple Leaf Medical Clinic","funders":"Janssen Pharmaceuticals; Raymond and Beverly Sackler Institute for Biological, Physical and Engineering Sciences, Yale University; Arthur Foundation; Johnson and Johnson; Gilead Sciences; Merck; Yale University","keywords":"Darunavir; Emtricitabine; Tenofovir alafenamide; Medicine; Internal medicine; Adverse effect; Cobicistat; Gastroenterology; Viral load; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004682942,0.0007272353,0.00205122,0.0006683177,0.0004169355,0.0001209459,0.0006918089,0.0002107227,0.0000374516],"category_scores_gemma":[0.003999675,0.0003776898,0.0002838121,0.002272336,0.000531924,0.0003575413,0.000713532,0.0007495413,0.00005120806],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007949669,"about_ca_system_score_gemma":0.001211618,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002497567,"about_ca_topic_score_gemma":0.0002966551,"domain_scores_codex":[0.9909232,0.00244182,0.001786169,0.001463039,0.002111089,0.001274701],"domain_scores_gemma":[0.9926049,0.004470679,0.0006093415,0.001463579,0.0005187762,0.0003327348],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8734399,0.003466234,0.003414258,0.00009829073,0.0005308661,0.0001502011,0.02544288,0.0002194591,0.08052601,0.00002764112,0.0004452717,0.012239],"study_design_scores_gemma":[0.913333,0.01343158,0.007004165,0.003645298,0.0004480559,0.00001114127,0.004112262,0.004363256,0.05199674,0.00005205001,0.0008505803,0.0007518709],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9746078,0.0003214788,0.0001028256,0.009004117,0.0001230348,0.01413374,0.0001816176,0.00004870652,0.001476659],"genre_scores_gemma":[0.9912064,0.0001559299,0.0008027208,0.0001589215,0.0001239466,0.0007403575,0.000108066,0.0000782579,0.006625365],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03989311,"threshold_uncertainty_score":0.9998675,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03428119433678359,"score_gpt":0.3278131052699593,"score_spread":0.2935319109331758,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}